| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $87.3M | +6.0% | +69.1% |
| R&D Expense | $14.1M | +95.2% | +35.9% |
| SG&A Expense | $41.8M | +5.9% | +4.7% |
| Operating Income | -$10.0M | -240.4% | +37.9% |
| Income Tax | $0 | — | — |
| Net Income | -$31.3M | -146.2% | -6.1% |
| EPS (Basic) | -$0.16 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $92.4M | +7.4% | -36.1% |
| Accounts Receivable | $119.0M | +10.4% | +75.4% |
| Inventory | $108.5M | -5.2% | +35.5% |
| Current Assets | $360.5M | +5.2% | +17.2% |
| Total Assets | $364.0M | +4.9% | +15.9% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$58.3M | — | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $6.0M | — | — |
| Free Cash Flow | -$58.3M | — | — |
| -6.7% |
| EPS (Diluted) | -$0.16 | -166.7% | -6.7% |
| $359.0M |
| +20.2% |
| +116.5% |
| Total Liabilities | $815.4M | +4.5% | +19.2% |
| Stockholders' Equity | -$451.4M | -4.1% | -21.9% |